<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR940617-1-00107</title>
	</head>
	<body>
		<main>
			<p><!-- PJG STAG 4702 -->  <!-- PJG ITAG l=11 g=1 f=1 --> (E)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Preparation of volunteers. <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  ( <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> 1 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> ) Instruct the  <!-- PJG 0012 frnewline --> volunteers to avoid contact with antimicrobials (other than the  <!-- PJG 0012 frnewline --> test formulation) for the duration of the test. This restriction  <!-- PJG 0012 frnewline --> includes antimicrobial containing antiperspirants, deodorants,  <!-- PJG 0012 frnewline --> shampoos, lotions, soaps, and materials such as acids, bases,  <!-- PJG 0012 frnewline --> solvents. Bathing in chlorinated pools and hot tubs should be  <!-- PJG 0012 frnewline --> avoided.  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline --> ( <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> 2 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> ) Volunteers are to be provided with a kit of  <!-- PJG 0012 frnewline --> nonantimicrobial personal care products for exclusive use during  <!-- PJG 0012 frnewline --> the test. Volunteers are not to shower or tub bathe in the 24-hour period prior to the application of test material or  <!-- PJG 0012 frnewline --> microbial sampling. Sponge baths may be taken but the skin sites  <!-- PJG 0012 frnewline --> to be used in the study are to be excluded.  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline --> ( <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> 3 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> ) If the skin sites to be used include areas that would  <!-- PJG 0012 frnewline --> require shaving prior to surgery, for example, the groin site,  <!-- PJG 0012 frnewline --> these sites should be shaved no later than 48 hours prior to the  <!-- PJG 0012 frnewline --> application of test formulation or microbial sampling.  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline --> ( <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> 4 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> ) After volunteers have refrained from using  <!-- PJG 0012 frnewline --> antimicrobials for at least 2 weeks, obtain an estimate of  <!-- PJG 0012 frnewline --> baseline bacterial population from one groin and one abdominal  <!-- PJG 0012 frnewline --> site at least 72 hours prior to entering subjects into the study.  <!-- PJG 0012 frnewline --> Sampling and enumeration techniques described in paragraphs  <!-- PJG 0012 frnewline --> (b)(3)(iii)(J) and (b)(3)(iii)(K) of this section are to be used.  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline --> ( <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> 5 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> ) Based on the initial estimate of baseline bacterial  <!-- PJG 0012 frnewline --> population, select sufficient numbers of subjects with high  <!-- PJG 0012 frnewline --> bacterial counts per formulation being tested to satisfy the  <!-- PJG 0012 frnewline --> statistical criteria of the clinical trial design.  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline --> (F)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Study design and randomization.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Subjects admitted to  <!-- PJG 0012 frnewline --> the study are to be identified as to whether they meet the groin  <!-- PJG 0012 frnewline --> portion or abdomen portion of the study, or both. Once a subject  <!-- PJG 0012 frnewline --> is admitted to the study, treatments are to be randomly assigned  <!-- PJG 0012 frnewline --> to one contralateral groin site, for subjects identified as  <!-- PJG 0012 frnewline --> belonging to this study group and similar treatments are to be  <!-- PJG 0012 frnewline --> randomly assigned to left or right side of the abdominal area,  <!-- PJG 0012 frnewline --> for subjects identified as belonging to the abdominal study  <!-- PJG 0012 frnewline --> group. This method of choosing subjects and sampling sites fits  <!-- PJG 0012 frnewline --> the paired comparison statistical design. Randomization of  <!-- PJG 0012 frnewline --> subjects to time periods and treatment to left or right side is  <!-- PJG 0012 frnewline --> to be accomplished in accordance with the plan similar to that  <!-- PJG 0012 frnewline --> presented for surgical hand scrub products.  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline --> (G)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Number of subjects required and statistical analysis  <!-- PJG 0012 frnewline --> of data. <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  ( <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> 1 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> ) Two ways to statistically evaluate effectiveness  <!-- PJG 0012 frnewline --> of a preoperative scrub product are presented. The first depends  <!-- PJG 0012 frnewline --> upon calculating the average log <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=2 --> 10 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  reduction from baseline. This  <!-- PJG 0012 frnewline --> is accomplished by obtaining the difference in log counts for  <!-- PJG 0012 frnewline --> each paired sample for each subject in the appropriate sampling  <!-- PJG 0012 frnewline --> time frame. This will facilitate subsequent statistical  <!-- PJG 0012 frnewline --> evaluation of resulting data. It is usually fairly easy to enroll  <!-- PJG 0012 frnewline --> subjects with counts 1&times;10 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=1 --> 5 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  or greater when working with the groin  <!-- PJG 0012 frnewline --> areas. It is anticipated this method will primarily be used to evaluate data collected from the groin areas. The sample size  <!-- PJG 0012 frnewline --> estimation equation given earlier may be used to estimate sample  <!-- PJG 0012 frnewline --> sizes required for this case. Standard deviations for  <!-- PJG 0012 frnewline --> preoperative scrub products are relatively homogeneous when  <!-- PJG 0012 frnewline --> inclusion criterion require counts of 1&times;10 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=1 --> 5 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  or greater. The  <!-- PJG 0012 frnewline --> standard deviations extracted from files range from 0.82 to 1.72;  <!-- PJG 0012 frnewline --> the median standard deviation was 0.98. When counts in the range  <!-- PJG 0012 frnewline --> of 1&times;10 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=1 --> 5 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  to 1&times;10 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=1 --> 6 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  were used, the standard deviation ranged from  <!-- PJG 0012 frnewline --> 0.78 to 1.22, with a median value of 0.99. Using the sample size  <!-- PJG 0012 frnewline --> estimation equation given in paragraph (b)(1)(iii)(F) of this  <!-- PJG 0012 frnewline --> section and assuming the active control preoperative scrub  <!-- PJG 0012 frnewline --> produces an immediate mean log reduction of 2.0 and test scrub is  <!-- PJG 0012 frnewline --> to be within 20 percent of this, i.e., D=0.4, and S <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=1 --> 2 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> =0.98, gives  <!-- PJG 0012 frnewline --> n=97 subjects per arm of the study. Because blocks of 6 are  <!-- PJG 0012 frnewline --> recommended, the sample size per treatment arm is 96 subjects.  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline --> ( <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> 2 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> ) The second method for evaluating the data depends upon  <!-- PJG 0012 frnewline --> establishing an entry target bacterial population of greater than  <!-- PJG 0012 frnewline --> 250 colony forming units per square centimeter and a target  <!-- PJG 0012 frnewline --> reduction criterion that a successful scrub reduces bacterial  <!-- PJG 0012 frnewline --> counts to below 25 colony forming units per square centimeter. A  <!-- PJG 0012 frnewline --> successful scrub product is to provide this degree of reduction  <!-- PJG 0012 frnewline --> in at least 90 percent of the subjects tested. Using the normal  <!-- PJG 0012 frnewline --> binomial confidence interval approach, it can be shown that if  <!-- PJG 0012 frnewline --> the standard preoperative scrub product achieves a 90 percent  <!-- PJG 0012 frnewline --> success rate and it is desired to rule out success rates less than 85 percent for the new product with power of 80 percent then  <!-- PJG 0012 frnewline --> 340 subjects per arm are required. If it is desired to rule out  <!-- PJG 0012 frnewline --> success rates less than 80 percent, then the sample size is only  <!-- PJG 0012 frnewline --> 100 per arm. Again, since blocks of 6 or some multiple thereof,  <!-- PJG 0012 frnewline --> are recommended, the sample size is 102 subjects per study arm.  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline --> ( <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> 3 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> ) In both cases described in paragraphs  <!-- PJG 0012 frnewline --> (b)(3)(iii)(G)( <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> 1 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> ) and (b)(3)(iii)(G)( <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> 2 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> ) of this section,  <!-- PJG 0012 frnewline --> effectiveness is judged based on calculation of 95 percent  <!-- PJG 0012 frnewline --> confidence intervals on the difference of the ``success rate for  <!-- PJG 0012 frnewline --> standard scrub product minus success rate for test scrub  <!-- PJG 0012 frnewline --> product.''  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline --> (H)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Treatment application procedure.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Apply treatment  <!-- PJG 0012 frnewline --> according to label directions or as stated in the proposed  <!-- PJG 0012 frnewline --> directions for test formulation. The control product is to be  <!-- PJG 0012 frnewline --> used according to the labeling directions.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG /STAG --></p>
		</main>
</body></html>
            